Developer docs
API playgroundTry for free, no card

Search company profiles

PixCell Medical

Full company profile

uuid0003ced

Namestring
PixCell Medical
Legal namestring
PixCell Medical Technologies Ltd.
Company typeenum
Private
Founded yearint
2009
Descriptiontext

PixCell Medical Technologies Ltd. is an Israel-based, privately held medical device company founded in 2009 and headquartered in Yokneam Ilit, with a US subsidiary in Longmont, Colorado. The company develops, manufactures, and commercializes the HemoScreen, a portable point-of-care Complete Blood Count (CBC) analyzer that delivers 20 CBC parameters including a 5-part differential from a single drop of blood in approximately five minutes. The platform is built on three proprietary technology pillars: Viscoelastic Focusing (VEF) microfluidics—protected by over 30 patents and discovered at Technion–Israel Institute of Technology—a single-use Lab-On-A-Cartridge with factory-calibrated reagents and contained sample handling, and AI-powered machine-vision classification of cells by morphology and staining. HemoScreen is FDA 510(k)-cleared as the only 5-part differential CBC analyzer cleared for Point of Care use, CE-marked, and classified as CLIA moderate-complexity, and it requires no maintenance, calibration, or specialized operator.

The business model is a classic razor-and-blade: capital sale of the portable HemoScreen reader plus recurring revenue from single-use cartridges consumed per test. PixCell commercializes primarily through a global distributor network—Katalyst Diagnostics (UK/Ireland), Werfen (Spain/Portugal), BioMed (Italy), BIOKOSMOS (Greece), Axonlab (Switzerland/Austria/Netherlands/Czech Republic), SoulBrain (South Korea), Alatheia (Chile), Point of Care Diagnostics (Australia/NZ), and Healthcare Technologies (South Africa)—combined with US distribution through Thermo Fisher Scientific, Henry Schein Medical Group, and Medline Industries, plus enterprise direct sales via a "Request a Demo" motion. End customers span emergency departments, urgent care clinics, oncology and hemato-oncology services, mental health (clozapine) clinics, primary care, pediatrics, blood banks, and military/field operations, with named deployments across NHS trusts in England, university hospitals in Sweden and Denmark, and clinics in Israel, Chile, Australia, and the US.

PixCell is led by co-founder and CEO Avishay Bransky, Ph.D., with a CCO, COO, CFO, dedicated US sales leadership, and a board that includes strategic investor Soulbrain Holdings representatives (Co-Chairman Nam Huh and Director Jongkook Park). Disclosed capital is modest: a 2018 EISMEA-linked raise of approximately $4.4M and a 2022 International Health-Tech Pilot Program grant. The company has signaled continued expansion through the 2020 Interreg Germany-Denmark Changing Cancer Care partnership for home-based cancer patient testing and the 2022 Charité Krankenhaus / Berlin Institute of Health collaboration for new clinical applications.

Short descriptiontext

PixCell Medical is an Israeli medical device company that develops and markets HemoScreen, an FDA-cleared portable point-of-care CBC analyzer using proprietary Viscoelastic Focusing microfluidics and AI-powered machine vision to deliver lab-quality blood diagnostics in five minutes from a single drop.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersYoqne`am `illit, Israel
HQ citystring
Yoqne`am `illit
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point of care diagnostics, hematology analyzers, complete blood count testing, microfluidic medical devices, portable blood diagnostics
Industry4 codes
PRIMARYHLAHAOAD
Hematology POCT (CBC/hemoglobin/hematocrit)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAAAF
Flow Cytometry & Cellular Analysis Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYCRADAMAK
Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
  • Analytical Laboratory Instrument Manufacturing334516
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Point-of-Care Hematology Analyzers
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1HemoScreen Analyzer Hardware
TypeHardware Sales
Description

Sale of the portable point-of-care hematology analyzer device

pixcell-medical.com
2Single-Use Cartridges
TypeUsage Based
Description

Disposable cartridges with integrated reagents for each test. Per-test payment model. Each cartridge includes all required reagents and is factory-calibrated.

pixcell-medical.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels13 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1HemoScreen™
Description

FDA-cleared portable Point of Care Complete Blood Count (CBC) analyzer with 5-part differential, using Viscoelastic Focusing (VEF) technology and AI-based machine vision analysis.

pixcell-medical.com
Core offering1 text field

PixCell Medical develops, manufactures, and markets the HemoScreen™ platform, a portable point-of-care hematology analyzer that performs a Complete Blood Count (CBC) with 5-part differential from a single drop of blood in approximately 5 minutes. The system consists of a reusable analyzer device and single-use factory-calibrated cartridges with integrated reagents, combining proprietary Viscoelastic Focusing (VEF) microfluidics, Lab-On-A-Cartridge design, and AI-powered machine vision for automated cell classification.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Results delivered in 5 minutes compared to 20+ minutes longer turnaround time in clinical labs
+3 more records
Product overview1 text field

PixCell Medical offers a single core product platform: the HemoScreen™ system, which consists of a portable hematology analyzer device and single-use cartridges. The platform performs Complete Blood Count (CBC) testing with 5-part differential at the point of care in approximately 5 minutes. The technology combines Viscoelastic Focusing (VEF) microfluidics, Lab-On-A-Cartridge design, and AI-powered machine vision for automated cell classification. The system delivers 20 standard CBC parameters and requires no maintenance, calibration, or reagent handling. Clinical settings include primary care, emergency medicine, oncology, pediatrics, blood centers, and military/field use.

Product and service2 records
1HemoScreen™ Hematology Analyzer
CategoryPoint-of-Care Hematology Analyzer (Hardware)
Description

Portable, FDA-cleared point-of-care Complete Blood Count (CBC) analyzer with 5-part differential for hospitals, urgent care clinics, oncology centers, primary care, mental health clinics, pediatrics, blood banks, and military/field use. Requires no maintenance, no calibration, and minimal training.

2HemoScreen™ Single-Use Test Cartridges
CategoryDiagnostic Consumables
Description

Disposable, factory-calibrated Lab-On-A-Cartridge consumables containing all required reagents for a CBC test; sealed to prevent cross-contamination and operated on a per-test payment model alongside the HemoScreen analyzer.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-22
Description

Collaboration with Charité Krankenhaus and Berlin Institute of Health under the International Health-Tech Pilot Program grant to develop new applications for the HemoScreen hematology analyzer and improve global patient care through international cooperation and technology validation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-22
Description

Collaboration with Charité Krankenhaus and Berlin Institute of Health under the International Health-Tech Pilot Program grant to develop new applications for the HemoScreen hematology analyzer and validate innovative medical technologies through international cooperation.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-05-01
Description

Flagship partnership to enable home-based blood testing for cancer patients in homecare settings, limiting immunocompromised patients' exposure to contagion in hospitals. Cancer patients in Denmark were trained to use HemoScreen to perform 5-part CBC tests to manage their treatments and support clinical decision-making.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

UK & Ireland distributor of HemoScreen products

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Spain & Portugal distributor of HemoScreen products

6BioMed Srl
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Italy distributor of HemoScreen products

pixcell-medical.com
7BIOKOSMOS MORIAKI S.A.
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Greece distributor of HemoScreen products

pixcell-medical.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Switzerland, Austria, Netherlands, and Czech Republic distributor of HemoScreen products

Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

US distribution partner for HemoScreen products - one of the world's largest distributors of laboratory and medical equipment

Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

US distribution partner for HemoScreen products - leading provider of health care products and services to physicians and practices

11Medline Industries
Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

US distribution partner for HemoScreen products - largest privately held manufacturer and distributor of medical supplies in the US

pixcell-medical.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Chile distributor of HemoScreen products

13SoulBrain
Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

South Korea distributor of HemoScreen products - also serves as a Board member through Soulbrain Holdings (Nam Huh, Ph.D., Co-Chairman and Director)

pixcell-medical.com
14Point of Care Diagnostics
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Australia & New Zealand distributor of HemoScreen products

pixcell-medical.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

South Africa distributor of HemoScreen products

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Markets the Atellica/ADVIA hematology lines for core labs and is actively pushing decentralized diagnostics. Broad incumbent with the breadth to bundle POC CBC with broader diagnostics portfolios.

2Beckman Coulter (Danaher)
TypeBroad incumbent
Description

Major clinical hematology franchise (DxH 900, DxH 500) within Danaher's Diagnostics platform. Broad incumbent offering overlapping CBC capability with the scale to launch a competing POC analyzer if economics warrant.

TypeDirect peer
Description

UK-based vendor of point-of-care analyzers including hemoglobin (Hemo Control) and other near-patient diagnostics. Compares to PixCell as a developer of small-footprint, decentralized hematology/POC devices for clinical and emerging-market customers.

4Sight Diagnostics
TypeDirect peer
Description

Israeli-AI blood diagnostics company whose OLO device delivers finger-prick, 5-part differential CBC at the point of care. Closest direct competitor to PixCell's HemoScreen, targeting the same small-sample, AI-vision-enabled POC hematology category.

TypeDirect peer
Description

Pioneer in capillary-sample, point-of-care hemoglobin testing, now part of Danaher/Radiometer. Most directly comparable on the finger-stick sample / decentralized POC value proposition PixCell pursues, even though HemoCue today primarily measures hemoglobin rather than full CBC.

TypeDirect peer
Description

Swedish manufacturer of compact, low-volume hematology analyzers (e.g., Medonic, Swelab) widely used in smaller labs, point-of-care, and emerging markets. Directly comparable as a compact CBC analyzer vendor targeting decentralized settings.

TypeDirect peer
Description

Hungarian manufacturer of compact hematology analyzers (Abacus) for small-to-mid labs and POC environments. Competes head-to-head with HemoScreen in decentralized CBC analyzer procurement decisions globally.

TypeBroad incumbent
Description

World-leading hematology analyzer company (XN-Series, pocH-100i) dominating hospital and reference-lab CBC. Broad incumbent whose installed base and scale could rapidly move into POC hematology if category adoption accelerates.

TypeRegional player
Description

Japan/France-based hematology analyzer vendor (Pentra, Yumizen) with compact CBC instruments. Comparable as a vendor of small-footprint CBC analyzers competing for similar hospital and outreach lab deployments, particularly in Europe and APAC.

10Abbott Point of Care
TypeBroad incumbent
Description

Markets the i-STAT and Piccolo systems used at the bedside for blood gas and basic chemistries. Broad incumbent in POC diagnostics that could expand its clinical menu to challenge HemoScreen in near-patient CBC.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PixCell Medical

Point-of-Care Hematology Analyzerspixcell-medical.com

PixCell Medical is an Israeli medical device company that develops and markets HemoScreen, an FDA-cleared portable point-of-care CBC analyzer using proprietary Viscoelastic Focusing microfluidics and AI-powered machine vision to deliver lab-quality blood diagnostics in five minutes from a single drop.

What PixCell Medical does

PixCell Medical Technologies Ltd. is an Israel-based, privately held medical device company founded in 2009 and headquartered in Yokneam Ilit, with a US subsidiary in Longmont, Colorado. The company develops, manufactures, and commercializes the HemoScreen, a portable point-of-care Complete Blood Count (CBC) analyzer that delivers 20 CBC parameters including a 5-part differential from a single drop of blood in approximately five minutes. The platform is built on three proprietary technology pillars: Viscoelastic Focusing (VEF) microfluidics—protected by over 30 patents and discovered at Technion–Israel Institute of Technology—a single-use Lab-On-A-Cartridge with factory-calibrated reagents and contained sample handling, and AI-powered machine-vision classification of cells by morphology and staining. HemoScreen is FDA 510(k)-cleared as the only 5-part differential CBC analyzer cleared for Point of Care use, CE-marked, and classified as CLIA moderate-complexity, and it requires no maintenance, calibration, or specialized operator.

The business model is a classic razor-and-blade: capital sale of the portable HemoScreen reader plus recurring revenue from single-use cartridges consumed per test. PixCell commercializes primarily through a global distributor network—Katalyst Diagnostics (UK/Ireland), Werfen (Spain/Portugal), BioMed (Italy), BIOKOSMOS (Greece), Axonlab (Switzerland/Austria/Netherlands/Czech Republic), SoulBrain (South Korea), Alatheia (Chile), Point of Care Diagnostics (Australia/NZ), and Healthcare Technologies (South Africa)—combined with US distribution through Thermo Fisher Scientific, Henry Schein Medical Group, and Medline Industries, plus enterprise direct sales via a "Request a Demo" motion. End customers span emergency departments, urgent care clinics, oncology and hemato-oncology services, mental health (clozapine) clinics, primary care, pediatrics, blood banks, and military/field operations, with named deployments across NHS trusts in England, university hospitals in Sweden and Denmark, and clinics in Israel, Chile, Australia, and the US.

PixCell is led by co-founder and CEO Avishay Bransky, Ph.D., with a CCO, COO, CFO, dedicated US sales leadership, and a board that includes strategic investor Soulbrain Holdings representatives (Co-Chairman Nam Huh and Director Jongkook Park). Disclosed capital is modest: a 2018 EISMEA-linked raise of approximately $4.4M and a 2022 International Health-Tech Pilot Program grant. The company has signaled continued expansion through the 2020 Interreg Germany-Denmark Changing Cancer Care partnership for home-based cancer patient testing and the 2022 Charité Krankenhaus / Berlin Institute of Health collaboration for new clinical applications.

PixCell Medical firmographics

Firmographics
Name
PixCell Medical
Legal name
PixCell Medical Technologies Ltd.
Website
https://pixcell-medical.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
51–100 employees
Short description
PixCell Medical is an Israeli medical device company that develops and markets HemoScreen, an FDA-cleared portable point-of-care CBC analyzer using proprietary Viscoelastic Focusing microfluidics and AI-powered machine vision to deliver lab-quality blood diagnostics in five minutes from a single drop.
Ownership category
akta.pro rank

PixCell Medical industry classification

Industry
Product category
Point-of-Care Hematology Analyzers
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAOAD
Hematology POCT (CBC/hemoglobin/hematocrit)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAAAF
Flow Cytometry & Cellular Analysis Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYCRADAMAK
Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Point of care diagnostics
  • Hematology analyzers
  • Complete blood count testing
  • Microfluidic medical devices
  • Portable blood diagnostics

Where PixCell Medical is headquartered

Location

Headquarters

HQ city
Yoqne`am `illit
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

PixCell Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. HemoScreen Analyzer Hardware: Sale of the portable point-of-care hematology analyzer device
  2. Single-Use Cartridges: Disposable cartridges with integrated reagents for each test. Per-test payment model. Each cartridge includes all required reagents and is factory-calibrated.

Go-to-market motion2 records

Distribution channels13 records

Marketing channels5 records

PixCell Medical product offering

Product offering

Core offering

PixCell Medical develops, manufactures, and markets the HemoScreen™ platform, a portable point-of-care hematology analyzer that performs a Complete Blood Count (CBC) with 5-part differential from a single drop of blood in approximately 5 minutes. The system consists of a reusable analyzer device and single-use factory-calibrated cartridges with integrated reagents, combining proprietary Viscoelastic Focusing (VEF) microfluidics, Lab-On-A-Cartridge design, and AI-powered machine vision for automated cell classification.

Product overview

PixCell Medical offers a single core product platform: the HemoScreen™ system, which consists of a portable hematology analyzer device and single-use cartridges. The platform performs Complete Blood Count (CBC) testing with 5-part differential at the point of care in approximately 5 minutes. The technology combines Viscoelastic Focusing (VEF) microfluidics, Lab-On-A-Cartridge design, and AI-powered machine vision for automated cell classification. The system delivers 20 standard CBC parameters and requires no maintenance, calibration, or reagent handling. Clinical settings include primary care, emergency medicine, oncology, pediatrics, blood centers, and military/field use.

Differentiator

Problem solved

Functional benefit

Brands

  • HemoScreen™: FDA-cleared portable Point of Care Complete Blood Count (CBC) analyzer with 5-part differential, using Viscoelastic Focusing (VEF) technology and AI-based machine vision analysis.

Products and services

  • HemoScreen™ Hematology Analyzer Portable, FDA-cleared point-of-care Complete Blood Count (CBC) analyzer with 5-part differential for hospitals, urgent care clinics, oncology centers, primary care, mental health clinics, pediatrics, blood banks, and military/field use. Requires no maintenance, no calibration, and minimal training.
  • HemoScreen™ Single-Use Test Cartridges Disposable, factory-calibrated Lab-On-A-Cartridge consumables containing all required reagents for a CBC test; sealed to prevent cross-contamination and operated on a per-test payment model alongside the HemoScreen analyzer.

Quantifiable outcome

  • Results delivered in 5 minutes compared to 20+ minutes longer turnaround time in clinical labs
  • +3 more outcomes

Companies that use PixCell Medical

Customer profile

Named customers11 records

Segments7 records

Ideal customer profiles4 records

PixCell Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

PixCell Medical partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and flagship.

  • Charité KrankenhauscoreStrategic or Co-development Partner · 22 February 2022Collaboration with Charité Krankenhaus and Berlin Institute of Health under the International Health-Tech Pilot Program grant to develop new applications for the HemoScreen hematology analyzer and improve global patient care through international cooperation and technology validation.
  • Berlin Institute of HealthcoreStrategic or Co-development Partner · 22 February 2022Collaboration with Charité Krankenhaus and Berlin Institute of Health under the International Health-Tech Pilot Program grant to develop new applications for the HemoScreen hematology analyzer and validate innovative medical technologies through international cooperation.
  • Interreg Germany-Denmark Changing Cancer Care (CCC)flagshipStrategic or Co-development Partner · 1 May 2020Flagship partnership to enable home-based blood testing for cancer patients in homecare settings, limiting immunocompromised patients' exposure to contagion in hospitals. Cancer patients in Denmark were trained to use HemoScreen to perform 5-part CBC tests to manage their treatments and support clinical decision-making.
  • Katalyst DiagnosticscoreChannel Partner/ Reseller/ DistributorUK & Ireland distributor of HemoScreen products
  • WerfencoreChannel Partner/ Reseller/ DistributorSpain & Portugal distributor of HemoScreen products
  • BioMed SrlcoreChannel Partner/ Reseller/ DistributorItaly distributor of HemoScreen products
  • BIOKOSMOS MORIAKI S.A.coreChannel Partner/ Reseller/ DistributorGreece distributor of HemoScreen products
  • AxonlabcoreChannel Partner/ Reseller/ DistributorSwitzerland, Austria, Netherlands, and Czech Republic distributor of HemoScreen products
  • Thermo Fisher ScientificflagshipChannel Partner/ Reseller/ DistributorUS distribution partner for HemoScreen products - one of the world's largest distributors of laboratory and medical equipment
  • Henry Schein Medical GroupflagshipChannel Partner/ Reseller/ DistributorUS distribution partner for HemoScreen products - leading provider of health care products and services to physicians and practices
  • Medline IndustriesflagshipChannel Partner/ Reseller/ DistributorUS distribution partner for HemoScreen products - largest privately held manufacturer and distributor of medical supplies in the US
  • AlatheiacoreChannel Partner/ Reseller/ DistributorChile distributor of HemoScreen products
  • SoulBrainflagshipChannel Partner/ Reseller/ DistributorSouth Korea distributor of HemoScreen products - also serves as a Board member through Soulbrain Holdings (Nam Huh, Ph.D., Co-Chairman and Director)
  • Point of Care DiagnosticscoreChannel Partner/ Reseller/ DistributorAustralia & New Zealand distributor of HemoScreen products
  • Healthcare TechnologiescoreChannel Partner/ Reseller/ DistributorSouth Africa distributor of HemoScreen products

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

PixCell Medical competitors and assessment

Company assessment

Broad incumbents

  • Siemens Healthineers: Markets the Atellica/ADVIA hematology lines for core labs and is actively pushing decentralized diagnostics. Broad incumbent with the breadth to bundle POC CBC with broader diagnostics portfolios.
  • Beckman Coulter (Danaher): Major clinical hematology franchise (DxH 900, DxH 500) within Danaher's Diagnostics platform. Broad incumbent offering overlapping CBC capability with the scale to launch a competing POC analyzer if economics warrant.
  • Sysmex Corporation: World-leading hematology analyzer company (XN-Series, pocH-100i) dominating hospital and reference-lab CBC. Broad incumbent whose installed base and scale could rapidly move into POC hematology if category adoption accelerates.
  • Abbott Point of Care: Markets the i-STAT and Piccolo systems used at the bedside for blood gas and basic chemistries. Broad incumbent in POC diagnostics that could expand its clinical menu to challenge HemoScreen in near-patient CBC.

Direct peers

  • EKF Diagnostics: UK-based vendor of point-of-care analyzers including hemoglobin (Hemo Control) and other near-patient diagnostics. Compares to PixCell as a developer of small-footprint, decentralized hematology/POC devices for clinical and emerging-market customers.
  • Sight Diagnostics: Israeli-AI blood diagnostics company whose OLO device delivers finger-prick, 5-part differential CBC at the point of care. Closest direct competitor to PixCell's HemoScreen, targeting the same small-sample, AI-vision-enabled POC hematology category.
  • HemoCue (Radiometer / Danaher): Pioneer in capillary-sample, point-of-care hemoglobin testing, now part of Danaher/Radiometer. Most directly comparable on the finger-stick sample / decentralized POC value proposition PixCell pursues, even though HemoCue today primarily measures hemoglobin rather than full CBC.
  • Boule Diagnostics: Swedish manufacturer of compact, low-volume hematology analyzers (e.g., Medonic, Swelab) widely used in smaller labs, point-of-care, and emerging markets. Directly comparable as a compact CBC analyzer vendor targeting decentralized settings.
  • Diatron MI Zrt. Hungarian manufacturer of compact hematology analyzers (Abacus) for small-to-mid labs and POC environments. Competes head-to-head with HemoScreen in decentralized CBC analyzer procurement decisions globally.

Regional players

  • HORIBA Medical: Japan/France-based hematology analyzer vendor (Pentra, Yumizen) with compact CBC instruments. Comparable as a vendor of small-footprint CBC analyzers competing for similar hospital and outreach lab deployments, particularly in Europe and APAC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

PixCell Medical social profiles

Digital presence

PixCell Medical compliance and trust

Trust signal

Compliance3 records

PixCell Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PixCell Medical leadership team

Management profile

Number of profiles

Profiles14 records

PixCell Medical funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PixCell Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PixCell Medical

What does PixCell Medical do?

PixCell Medical develops, manufactures, and markets the HemoScreen™ platform, a portable point-of-care hematology analyzer that performs a Complete Blood Count (CBC) with 5-part differential from a single drop of blood in approximately 5 minutes. The system consists of a reusable analyzer device and single-use factory-calibrated cartridges with integrated reagents, combining proprietary Viscoelastic Focusing (VEF) microfluidics, Lab-On-A-Cartridge design, and AI-powered machine vision for automated cell classification.

Is PixCell Medical a public or private company?

PixCell Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was PixCell Medical founded?

PixCell Medical was founded in 2009. It employs 51 to 100 people.

Where is PixCell Medical based?

PixCell Medical is headquartered in Yoqne`am `illit, Israel, in the Middle East region.

How does PixCell Medical make money?

Two revenue lines are on record. HemoScreen Analyzer Hardware is the primary driver. The others are single-Use Cartridges.

Who are PixCell Medical's main competitors?

Broad incumbents on record are Siemens Healthineers, Beckman Coulter (Danaher), Sysmex Corporation and Abbott Point of Care. Direct peers are EKF Diagnostics, Sight Diagnostics, HemoCue (Radiometer / Danaher), Boule Diagnostics and Diatron MI Zrt.. HORIBA Medical is listed as a regional player.

Does PixCell Medical have an API?

No public API is recorded for PixCell Medical.

What industry is PixCell Medical in?

PixCell Medical's product category is Point-of-Care Hematology Analyzers. Its primary akta.pro industry code is HLAHAOAD, Hematology POCT (CBC/hemoglobin/hematocrit), with a secondary code of HLAHAAAF, Flow Cytometry & Cellular Analysis Diagnostics. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooPixCell Medical and Inter Medico to distribute HemoScreen across CanadaPixCell Medical has partnered with Inter Medico to distribute its HemoScreen point-of-care haematology analyser across Canada, following the receipt of a Class III Medical Device License from Health Canada. The device enables rapid, laboratory-quality complete blood count testing using AI-based imaging and requires no maintenance or external reagents. This expansion aims to provide decentralized diagnostic solutions to hospitals, clinics, and remote healthcare sites throughout the country.Medical Device NetworkPixCell Medical and Inter Medico to distribute HemoScreen across CanadaPixCell Medical entered the Canadian market via a distribution agreement with Inter Medico after receiving a Class III Medical Device License for its HemoScreen analyser. The device enables rapid CBC testing from a single blood drop, targeting hospitals, clinics, and remote sites. Inter Medico will handle distribution, support, and field service.BioSpacePixCell Medical Expands into Canada Through Partnership with Inter Medico Following Health Canada Class III Licence for HemoScreenPixCell Medical received a Health Canada Class III license for its HemoScreen point-of-care hematology analyzer and partnered with Inter Medico to expand into Canada. The device enables lab-quality CBC testing from a single blood drop, targeting rural and remote healthcare settings. The partnership aims to make decentralized diagnostics more accessible across the country.PR NewswireHemoScreen Now Deployed Across More Than One-Third of NHS Mental Health Trusts, Supporting a New Integrated Diagnostics Model in Psychiatric HealthcarePixCell Medical's HemoScreen point-of-care complete blood count analyzer has been deployed across more than one-third of NHS mental health trusts in the United Kingdom, reaching over 100 NHS mental health clinics. Initially introduced for clozapine monitoring, the device has expanded into routine clinical practice across community mental health clinics, inpatient wards, and secure psychiatric units, addressing challenges such as needle phobia, transport requirements, and operational pressures. Major NHS trusts including Oxford University Hospitals, South London and Maudsley, Kent and Medway, Cumbria Northumberland Tyne and Wear, and Birmingham and Solihull have adopted the technology.openPR.comPortable Diagnostic Device Market In-depth Insights, Business Opportunities and top companies Analysis forecast by 2032 | PixCell, PT. RAFA Topaz Utama, Siemens AGThe portable diagnostic device market is projected to grow at a CAGR of 11.30% from 2025 to 2032. Growth is driven by increasing point-of-care testing demand, technological advancements, rising chronic diseases, and telehealth adoption. Key players include PixCell, Siemens AG, and Roche.PR NewswirePixCell Medical's HemoScreen CBC Analyzer Achieves IVDR Certification--A Game-Changer for Point-of-Care DiagnosticsPixCell Medical announced that its HemoScreen CBC analyzer achieved IVDR certification, becoming the first point-of-care 5-part differential CBC analyzer to meet the regulation. The certification, conducted by Dekra, validates the device's clinical performance and safety, and was secured years ahead of the regulatory deadline.PR NewswirePixCell Medical Partners with Healthcare Giants Medline, Henry Schein, and Fisher Scientific to Distribute HemoScreen Point of Care CBC Analyzer Across the USAPixCell Medical announced strategic distribution partnerships with Medline, Henry Schein, and Thermo Fisher Scientific to expand availability of its HemoScreen point-of-care Complete Blood Count analyzer across the United States. The agreements represent a significant milestone in PixCell Medical's U.S. market expansion strategy, leveraging the distributors' established healthcare supply networks. The HemoScreen provides lab-accurate CBC results within five minutes using a portable, cartridge-based platform designed for point-of-care settings including clinics, emergency departments, and laboratories.PR NewswireResearch Team at UNC Validates PixCell Medical's HemoScreen as Game-Changer for Clozapine Monitoring in PsychiatryA research team at the University of North Carolina conducted a study evaluating three point-of-care complete blood count analyzers for monitoring patients on Clozapine therapy for treatment-resistant schizophrenia, finding PixCell Medical's HemoScreen to be the superior option with 89.5% clinical concordance at medical decision thresholds for Absolute Neutrophil Count. The HemoScreen device demonstrated exceptional accuracy and precision compared to Sight OLO and Sysmex pocH-100i, with the added advantage of fingerstick sampling that can improve treatment adherence. The study validates HemoScreen as a viable near-patient testing solution to address the underutilization of Clozapine, which is linked to agranulocytosis risk and the burden of frequent blood monitoring requirements.PR NewswireClinical Evaluation Concludes PixCell Medical's HemoScreen is an Accurate and Easy-to-Use Point-of-Care Analyzer for Psychiatric Companion DiagnosticsResearchers at South London and Maudsley NHS Foundation Trust conducted a clinical evaluation of 226 Clozapine-treated patients and found strong correlations between standard lab venous methods and PixCell Medical's HemoScreen capillary and venous assays. The study, published in the Journal of Psychiatric Research, concluded that HemoScreen is viable for finger-prick companion diagnostics, offering a portable and accurate alternative to current non-portable blood monitoring methods. This finding has the potential to substantially improve Clozapine treatment enrollment and adherence among psychiatric patients who often experience severe needle anxiety with traditional venous blood draws.BioSpacePixCell Medical Names Mark Erez as Chief Financial OfficerPixCell Medical appointed Mark Erez as its new Chief Financial Officer, effective June 8, 2022. Erez brings over two decades of financial experience, including six years as CFO of Home Skinovations. He will oversee financial planning to support the company's global commercial expansion.